JP6407288B2 - 抗菌性1h−インダゾール及び1h−インドール誘導体 - Google Patents

抗菌性1h−インダゾール及び1h−インドール誘導体 Download PDF

Info

Publication number
JP6407288B2
JP6407288B2 JP2016541300A JP2016541300A JP6407288B2 JP 6407288 B2 JP6407288 B2 JP 6407288B2 JP 2016541300 A JP2016541300 A JP 2016541300A JP 2016541300 A JP2016541300 A JP 2016541300A JP 6407288 B2 JP6407288 B2 JP 6407288B2
Authority
JP
Japan
Prior art keywords
hydroxy
methyl
methylsulfonyl
butanamide
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016541300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500336A (ja
Inventor
ウブシュヴェーレン クリスチャン
ウブシュヴェーレン クリスチャン
オシャラ エティエンヌ
オシャラ エティエンヌ
スペックリン ジャン−リュック
スペックリン ジャン−リュック
スリヴェット ジャン−フィリップ
スリヴェット ジャン−フィリップ
ミッレ アゼリー
ミッレ アゼリー
シャポー ガエル
シャポー ガエル
ゴーヴァン ジャン−クリストフ
ゴーヴァン ジャン−クリストフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2017500336A publication Critical patent/JP2017500336A/ja
Application granted granted Critical
Publication of JP6407288B2 publication Critical patent/JP6407288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016541300A 2013-12-19 2014-12-18 抗菌性1h−インダゾール及び1h−インドール誘導体 Expired - Fee Related JP6407288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198338 2013-12-19
EP13198338.9 2013-12-19
PCT/EP2014/078384 WO2015091741A1 (en) 2013-12-19 2014-12-18 Antibacterial 1h-indazole and 1h-indole derivatives

Publications (2)

Publication Number Publication Date
JP2017500336A JP2017500336A (ja) 2017-01-05
JP6407288B2 true JP6407288B2 (ja) 2018-10-17

Family

ID=49880464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541300A Expired - Fee Related JP6407288B2 (ja) 2013-12-19 2014-12-18 抗菌性1h−インダゾール及び1h−インドール誘導体

Country Status (22)

Country Link
US (1) US9624206B2 (enExample)
EP (1) EP3083567B1 (enExample)
JP (1) JP6407288B2 (enExample)
KR (1) KR20160098503A (enExample)
CN (1) CN105829288B (enExample)
AR (1) AR100032A1 (enExample)
AU (1) AU2014368619B2 (enExample)
BR (1) BR112016014115A8 (enExample)
CA (1) CA2933604A1 (enExample)
CL (1) CL2016001524A1 (enExample)
EA (1) EA030730B1 (enExample)
ES (1) ES2666130T3 (enExample)
IL (1) IL246201A0 (enExample)
MA (1) MA39189A1 (enExample)
MX (1) MX360983B (enExample)
PH (1) PH12016501102A1 (enExample)
PL (1) PL3083567T3 (enExample)
SG (1) SG11201605014YA (enExample)
TR (1) TR201807881T4 (enExample)
TW (1) TW201609641A (enExample)
WO (1) WO2015091741A1 (enExample)
ZA (1) ZA201604968B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
BR112017010474A2 (pt) 2014-11-19 2017-12-26 Actelion Pharmaceuticals Ltd derivados antibacterianos de benzotiazol
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105839A1 (es) * 2015-08-28 2017-11-15 Actelion Pharmaceuticals Ltd Derivados antibacterianos pirrolidin-2-ona anulares
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
AU2017267194A1 (en) * 2016-05-17 2019-01-17 Idorsia Pharmaceuticals Ltd 6-(BUTA-1,3-DIYN-1-YL)benzo[D]thiazole derivatives
WO2018216822A1 (en) 2017-05-25 2018-11-29 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivatives
WO2019086452A1 (en) * 2017-10-31 2019-05-09 Idorsia Pharmaceuticals Ltd Antibacterial heteroaromatic compounds
CN113666860B (zh) * 2020-05-14 2024-03-15 鲁南制药集团股份有限公司 一种7-乙基色醇的制备方法
CN119014415B (zh) * 2024-08-19 2025-09-05 浙江大学 1-甲氧基吲哚在驱避和/或杀灭害虫中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4931823B2 (ja) 2004-10-18 2012-05-16 アムジエン・インコーポレーテツド チアジアゾール化合物及び使用方法
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2638006A1 (en) 2010-11-10 2013-09-18 Achaogen, Inc. Hydroxamic acid derivatives and their use in the treatment of bacterial infections
KR20120079015A (ko) 2011-01-03 2012-07-11 한미약품 주식회사 G 단백질-커플링된 수용체의 조절을 위한 신규한 비사이클릭 화합물
AP3336A (en) * 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
WO2012137099A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Also Published As

Publication number Publication date
TW201609641A (zh) 2016-03-16
IL246201A0 (en) 2016-08-02
US20170029411A1 (en) 2017-02-02
MX2016007991A (es) 2016-10-07
JP2017500336A (ja) 2017-01-05
EA030730B1 (ru) 2018-09-28
EP3083567B1 (en) 2018-03-07
CA2933604A1 (en) 2015-06-25
AU2014368619A1 (en) 2016-07-28
SG11201605014YA (en) 2016-07-28
ZA201604968B (en) 2018-11-28
CL2016001524A1 (es) 2017-01-27
EA201600475A1 (ru) 2016-11-30
MA39189A1 (fr) 2017-06-30
CN105829288B (zh) 2019-01-15
AR100032A1 (es) 2016-09-07
CN105829288A (zh) 2016-08-03
WO2015091741A1 (en) 2015-06-25
TR201807881T4 (tr) 2018-06-21
PH12016501102A1 (en) 2016-07-11
PL3083567T3 (pl) 2018-08-31
AU2014368619B2 (en) 2018-11-22
MX360983B (es) 2018-11-22
US9624206B2 (en) 2017-04-18
BR112016014115A2 (enExample) 2017-08-08
ES2666130T3 (es) 2018-05-03
BR112016014115A8 (pt) 2017-12-26
KR20160098503A (ko) 2016-08-18
EP3083567A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
US9624206B2 (en) Antibacterial 1H-indazole and 1H-indole derivatives
JP6353909B2 (ja) 抗菌性2h−インダゾール誘導体
JP6516370B2 (ja) 1,2−ジヒドロ−3H−ピロロ[1,2−c]イミダゾール−3−オン誘導体及び抗菌剤としてのそれらの使用
US9796686B2 (en) Antibacterial quinazoline-4(3H)-one derivatives
JP2018526391A (ja) 置換1,2−ジヒドロ−3H−ピロロ[1,2−c]イミダゾール−3−オン抗菌性化合物
JP2018526354A (ja) 置換1,2−ジヒドロ−3H−ピロロ[1,2−c]イミダゾール−3−オン抗菌剤
EP3221300B1 (en) Antibacterial benzothiazole derivatives
JP2018531902A (ja) 抗菌性縮合ピロリジン−2−オン誘導体
JP2018527349A (ja) 抗菌性ヘテロ環誘導体
HK1227031B (en) Antibacterial 2h-indazole derivatives
HK1227031A1 (en) Antibacterial 2h-indazole derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171212

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180918

R150 Certificate of patent or registration of utility model

Ref document number: 6407288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees